Summary A total of 610 patients with small cell lung cancer were entered into a randomised trial designed to assess the effect of duration of initial chemotherapy on survival. Patients were randomised to receive either four or eight courses of cytotoxic chemotherapy with cyclophosphamide, vincristine and etoposide and also randomised to receive, on disease progression, either second line chemotherapy ( Stopping chemotherapy early may improve the quality of life of the patients by minimising toxicity, but in responding patients may diminish survival unless further chemotherapy is effective on relapse. Although response to chemotherapy at relapse is usually clinically disappointing, Evans et al. (1985) recorded a 55% response rate with cisplatin and etoposide after previous treatment with cyclophosphamide, adriamycin and vincristine.
Although combination chemotherapy has improved median survival in small cell lung cancer (SCLC) it is increasingly clear that long-term survival is confined to those with both limited disease and good performance status (PS) who constitute approximately 20% of all cases (Osterlind & Andersen, 1986; Souhami et al., 1985) . Intensive or prolonged therapy would be justifiable for these good prognosis patients if it improved survival, but most patients present with extensive disease, poor performance status or advanced age. For these patients, chemotherapy is palliative. The optimal duration of chemotherapy has not been established with certainty. Cullen et al. (1986) administered six courses of chemotherapy and the patients with no unequivocal residual disease were randomised to either symptomatic treatment or a further eight courses of maintenance chemotherapy. A survival advantage was shown for those with extensive disease receiving maintenance therapy. An EORTC study (Splinter et al., 1986 ) with a similar design showed no advantage for 12 courses of monthly maintenance therapy.
Stopping chemotherapy early may improve the quality of life of the patients by minimising toxicity, but in responding patients may diminish survival unless further chemotherapy is effective on relapse. Although response to chemotherapy at relapse is usually clinically disappointing, Evans et al. (1985) recorded a 55% response rate with cisplatin and etoposide after previous treatment with cyclophosphamide, adriamycin and vincristine.
We report here a large scale randomised trial designed to assess the effects of duration of chemotherapy on survival in patients with SCLC. The trial evaluates the effect of either 3 or 6 months' chemotherapy and then, at relapse, the effects of further chemotherapy compared with symptomatic treatment alone.
hospitals. All At diagnosis there was a double randomisation of treatment. The randomisations were stratified by stage of disease (limited or extensive). The first randomisation was to receive either four or eight courses of initial cytotoxic chemotherapy (short course or long course respectively). The treatment regimen was cyclophosphamide I gm-2 i.v.; vincristine 1.4 mgm -2 i.v. (maximum dose 2 mg) both on day 1 and etoposide capsules 100mg orally eight hourly on days 1-3 (total dose 900mg). Each treatment was given every 21 days provided that the total white cell count on the day of treatment was equal to or greater than 3,500 mm3 and the platelet count equal to, or greater than 100,000 mm3. If not, treatment dosage was reduced according to the following schedule. If the total white cell count was 3,499-3,000, 75% of cyclophosphamide and 700mg etoposide was given, and if less than 3,000, the treatment was omitted and the blood count repeated a week later. The number of patients required was determined before the trial began and was based on the ability to detect a 10% difference in overall survival from 20 to 30% at one year.
This required 551 patients to be randomised using 0.05 and 0.90 as the type I and II errors respectively (Freedman, 1982) . The estimation was based on survival data in previous studies with a 25% survival at one year (Souhami et al., 1984) . It was assumed that the survival may be less with fewer courses of initial chemotherapy. Survival curves were constructed according to the method of Kaplan & Meier (1958) and statistical significance evaluated by the log-rank test (Peto et al., 1977) . To ensure that where no difference was seen between two curves the result was likely to be a true negative the power of the test was computed according to Hughes (1981) . The probability that the result is not a false negative is given, in addition to the usual P value.
Results
Of the 616 patients entering the study between The overall survival for all patients, based on the initial randomisation, is shown in Figure 1 . There was no significant difference between the two survival curves (P=0.085), but median survival in the patients randomised to long course chemotherapy was 39 weeks, compared with 32 weeks in those receiving short course treatment (false negative P = 0.007).
The combined results (Figure 2) show that of the four treatment policies, four courses of chemotherapy alone gives inferior survival to the other three treatments, which are equivalent in outcome. Thus, if chemotherapy is given on relapse, there is no survival disadvantage when initial treatment is stopped after four cycles. In contrast, in those ( Figure 3 ). During the initial three months of the study, when all patients were receiving chemotherapy, the rates of relapse were similar but the rate of progression increased in the short course group once chemotherapy had ceased. The median progression-free intervals were 23 and 31 weeks for short and long course patients respectively (P<0.001). Figure 4 shows the survival curves from relapse to death. For patients treated with short or long course chemotherapy, who were randomised to receive symptomatic treatment only at relapse, the curves are identical with median survivals of 11 and 12 weeks. In the patients randomised to further chemotherapy at relapse, survival from relapse was better than with symptomatic treatment. Median survival was 15 weeks for those allocated to long course chemotherapy, and 20 weeks for those allocated to receive short course treatment. Comparing the four curves in Figure 4 , survival from relapse was longer for those patients receiving short course and allocated to relapse chemotherapy.
When the effects of the treatment policies are separated according to disease extent the results are as shown in Table  VII patients with limited disease the proportion of 24-month survivors was lowest in those treated with four chemotherapy cycles alone (although this was less apparent at 36 months). If the study is analysed further to include only the responding population, the disadvantage of giving four courses of chemotherapy alone becomes more apparent. Figure 5 shows the survival curves for the responding population randomised to receive short and symptomatic treatment versus long and symptomatic. The survival curve for the long treatment arm is significantly better (P=0.01) than for the short and a difference is still apparent at two years. The other two randomisations (Figure 6) show no difference for the responders receiving short and relapse or long and relapse chemotherapy (false negative P=0.002).
Toxicity data included all deaths considered to be directly attributable to drug toxicity. There were 18 in the short course and 11 in the long course chemotherapy arms. However, the death rate in early cycles is not randomly distributed during the inter-cycle period and we have shown, and will report separately, that it is likely that chemotherapy induced toxicity contributes to early deat-h in patients with extensive disease. The number of reported episodes of serious infection (WHO grade 2) was 45 during short course chemotherapy and 70 during long. Recorded episodes of total white cell count falling below 3,000 or a neutropenia of 1,000 before a course of chemotherapy was 55 during short course and 182 during the long course treatment. Courses were delayed a total of 71 and 217 times during short and long course treatment respectively. Activity, mood, pain, nausea and vomiting were assessed in detail using daily diary cards as part of a study on quality of life which will be reported separately. In summary, mild nausea and vomiting occurred in almost all patients but continued longer in those receiving eight cycles of treatment. Hair loss was universal. Severe (WHO grade 2) mucositis occurred in 16 and 35 patients respectively, and neuropathy on four and 15 occasions during the short and long courses.
Discussion
This is one of the largest studies to address the effects of length of chemotherapy in patients with SCLC. The major referring centres within the multicentre group enter all patients presenting with the disease who are judged likely to survive a minimum of three weeks if left untreated, and the patients are therefore representative of the disease pattern within the community. Since the overall prognosis of SCLC is poor (Davis et al., 1985) and many patients are elderly and of poor performance status, the duration of chemotherapy is an important practical consideration. There have been few studies addressing this question. Cullen et al. (1986) evaluated maintenance chemotherapy versus no treatment in patients with no unequivocal residual disease after induction therapy and found a 16-week advantage for continuing chemotherapy. In the EORTC study (Splinter et al., 1986) five initial courses of chemotherapy were followed by a randomisation in the responding population either to a further seven courses of drug treatment or symptomatic treatment. There was no survival advantage for further chemotherapy in limited disease patients but a small advantage for extensive disease patients. There has been no study evaluating different durations of initial chemotherapy and the effect of further chemotherapy after relapse. The UK MRC Lung Cancer Working Party have compared six and 12 courses of chemotherapy and found no difference in median or 3-year survival (D. Girling, personal communication).
In our study, where treatment was stopped after only 12 weeks of chemotherapy in half the patients, the issue of what to do at relapse was important because the early cessation of therapy, especially in patients responding to treatment, may result in an unacceptably worse survival. For this reason we adopted a second randomisation which posed the question of the possible benefits of second line chemotherapy. The initial chemotherapy used widely accepted drugs active in small cell lung cancer (Hansen & R0rth, 1979) . The second line drugs, methotrexate and doxorubicin, were of different classes, modes of action and are also active against the disease.
The results of this study show that continuing initial chemotherapy for eight courses does not greatly increase the response rate compared with four courses. However, stopping chemotherapy after four cycles resulted in earlier disease progression. At progression, there was a clear survival advantage for second line chemotherapy in those previously receiving short course chemotherapy, but this was less apparent in those given eight cycles. The overall study design therefore showed that four cycles of chemotherapy alone resulted in worse survival, but any of the other treatment policies equal. This disadvantage of short course chemotherapy alone was particularly obvious in the responding population both in median and 2-year survival.
The study analysis is based on intention to treat but it must be noted that many patients failed during initial chemotherapy and that the clinicians in charge sometimes felt that an individual was too ill to undergo relapse chemotherapy. Furthermore, some patients refused chemotherapy on relapse. Patients dropping out of the study are particularly likely to be patients with poor performance status and/or extensive disease.
The study has shown that intention to treat with chemotherapy at relapse was harder to realise with long course chemotherapy. Less than 50% of patients allocated to relapse chemotherapy following long course treatment were either willing or able to receive it. It can be concluded from this study that the policy of stopping treatment early will lead to earlier relapse. In the group as a whole no survival disadvantage results provided chemotherapy is given on relapse, and clinicians might judge that in some circumstances this may be a convenient treatment policy; for example in treating elderly and poor prognosis patients or in those with particularly severe side-effects of treatment. However, taken together with the other studies (Cullen et al., 1986; Evans et al., 1985; Splinter et al., 1986 ) the present results show that there is a limit to the degree to which chemotherapy can be reduced without a deterioration in survival especially in those responding to treatment. The data from this study and from the MRC trial indicate that, for the majority of patients, six cycles of chemotherapy represents adequate treatment with combination chemotherapy programmes similar to those used in these two studies. Further improvements await new drug combinations and schedules for good prognosis limited disease patients and better palliative regimens for the others.
